Kazuto Yamazaki

Title: Kazuto Yamazaki: Innovator in Antitumor Compounds

Introduction

Kazuto Yamazaki is a notable inventor based in Ikoma, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antitumor effects. His innovative work has led to the filing of multiple patents, showcasing his expertise and dedication to advancing medical science.

Latest Patents

Kazuto Yamazaki holds 4 patents related to optically active azabicyclo ring derivatives. His latest patents describe a compound of formula (1a) wherein p is 1 or 2, R is a hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof. This compound has demonstrated an antitumor effect by inhibiting the binding between a MLL fusion protein infused with AF4, AF9, or similar agents, which are known to be representative fusion partner genes causing MLL leukemia, and menin.

Career Highlights

Throughout his career, Kazuto Yamazaki has worked with prominent companies in the pharmaceutical industry, including Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in cancer treatment.

Collaborations

Kazuto has collaborated with esteemed colleagues such as Seiji Kamioka and Hitoshi Ban. These partnerships have fostered an environment of innovation and have been instrumental in the development of his patented compounds.

Conclusion

Kazuto Yamazaki's contributions to the field of pharmaceuticals, particularly in the area of antitumor compounds, highlight his role as a significant inventor. His work continues to impact the medical community and offers hope for advancements in cancer treatment.